Lakefront Biotherapeutics | GLPG - Selling And Administration Expenses


Lakefront Biotherapeutics reported EUR35.5M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
argenx SE USD 355M 74.62M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
Genmab DKK 208M 60M Dec/2025
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
GRIFOLS EUR 281M 5.7M Mar/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Incyte USD 328.1M 62.31M Mar/2026
Merck EUR 1.52B 80M Mar/2026
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.33B 419M Mar/2026
UCB EUR 1.47B 193M Dec/2025
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026